Astellas Pharma ADR (ALPMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
| 09-2017 | 06-2017 | 12-2016 | 09-2016 | 06-2016 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 911,016 | 436,239 | 2,243,862 | 1,546,166 | 866,611 |
| Depreciation Amortization | 289,917 | 143,964 | 436,862 | 308,612 | 148,521 |
| Accounts receivable | 86,391 | -177,867 | -241,362 | -191,120 | -340,733 |
| Accounts payable and accrued liabilities | -594,513 | -391,491 | -61,622 | -70,384 | -48,853 |
| Other Working Capital | -565,029 | -450,279 | -797,511 | -740,370 | -706,874 |
| Other Operating Activity | 909,540 | 974,862 | 134,679 | 29,831 | 250,124 |
| Operating Cash Flow | $1,037,322 | $535,428 | $1,714,908 | $882,735 | $168,795 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -88,821 | -20,151 | -188,517 | -152,635 | -64,496 |
| Net Acquisitions | -554,103 | -498,303 | -468,418 | N/A | N/A |
| Purchase Of Investment | -6,246 | -1,161 | -4,379 | -2,342 | -1,758 |
| Sale Of Investment | 62,631 | 62,586 | 161,028 | 20,227 | 9,235 |
| Purchase Sale Intangibles | -50,364 | -32,850 | -140,217 | -49,196 | -9,412 |
| Other Investing Activity | -67,455 | -47,205 | -150,981 | -60,241 | -4,204 |
| Investing Cash Flow | $-653,994 | $-504,234 | $-651,268 | $-194,991 | $-61,222 |
| Cash Flows From Financing Activities | |||||
| Common Stock Repurchased | -451,575 | -6,372 | -429,318 | -7,517 | -7,115 |
| Dividend Paid | -315,945 | -315,945 | -645,095 | -333,200 | -316,200 |
| Other Financing Activity | -5,337 | -3,069 | -31,547 | -7,624 | -4,390 |
| Financing Cash Flow | $-772,857 | $-325,386 | $-1,105,960 | $-348,341 | $-327,704 |
| Exchange Rate Effect | 92,529 | 55,638 | -62,293 | -277,703 | -226,688 |
| Beginning Cash Position | 3,068,307 | 3,068,307 | 3,312,276 | 3,528,294 | 3,348,279 |
| End Cash Position | 2,771,307 | 2,829,753 | 3,207,672 | 3,589,985 | 2,901,460 |
| Net Cash Flow | $-297,000 | $-238,554 | $-104,604 | $61,701 | $-446,809 |
| Free Cash Flow | |||||
| Operating Cash Flow | 1,037,322 | 535,428 | 1,714,908 | 882,735 | 168,795 |
| Capital Expenditure | -91,998 | -21,492 | -194,451 | -158,211 | -69,006 |
| Free Cash Flow | 945,324 | 513,936 | 1,520,457 | 724,524 | 99,789 |